BREAKING
Agilent Q1 Revenue Rises 7%, Net Income Declines 17 hours ago Synopsys Q1 2026 Earnings Results 19 hours ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 20 hours ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 20 hours ago Key metrics from Lowe’s (LOW) Q4 2025 earnings results 2 days ago Earnings Preview: Best Buy (BBY) expected to report lower earnings in Q4 2026 3 days ago Apple Inc. (AAPL) Surges 5.1% — Developing Story 3 days ago Mastercard Incorporated (MA) Drops 5.6% — Developing Story 3 days ago UnitedHealth Group Incorporated (UNH) Drops 5.8% — Developing Story 3 days ago Accenture plc (ACN) Drops 6.0% — Developing Story 3 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 17 hours ago Synopsys Q1 2026 Earnings Results 19 hours ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 20 hours ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 20 hours ago Key metrics from Lowe’s (LOW) Q4 2025 earnings results 2 days ago Earnings Preview: Best Buy (BBY) expected to report lower earnings in Q4 2026 3 days ago Apple Inc. (AAPL) Surges 5.1% — Developing Story 3 days ago Mastercard Incorporated (MA) Drops 5.6% — Developing Story 3 days ago UnitedHealth Group Incorporated (UNH) Drops 5.8% — Developing Story 3 days ago Accenture plc (ACN) Drops 6.0% — Developing Story 3 days ago
ADVERTISEMENT
Market News

Earnings Summary: Quest Diagnostics (DGX) reaffirms FY25 guidance

Quest Diagnostics Incorporated (NYSE: DGX), a provider of diagnostic information services, has reaffirmed its outlook for fiscal 2025 and provided cautious first-quarter guidance. Quest said it continues to expect full-year 2025 net revenue to be in the range of $10.70 billion to $10.85 billion The guidance represents an 8.4% to $9.9% increase in full-year net […]

$DGX March 20, 2025 1 min read
NYSE
$DGX · Earnings

Quest Diagnostics Incorporated (NYSE: DGX), a provider of diagnostic information services, has reaffirmed its outlook for fiscal 2025 and provided cautious first-quarter guidance. Quest said it continues to expect full-year 2025 net revenue to be in the range of $10.70 billion to $10.85 billion The guidance represents an 8.4% to $9.9% increase in full-year net […]

· March 20, 2025

Quest Diagnostics Incorporated (NYSE: DGX), a provider of diagnostic information services, has reaffirmed its outlook for fiscal 2025 and provided cautious first-quarter guidance.

  • Quest said it continues to expect full-year 2025 net revenue to be in the range of $10.70 billion to $10.85 billion
  • The guidance represents an 8.4% to $9.9% increase in full-year net revenue
  • The company reaffirmed its earnings per share guidance for FY25, on a reported basis, in the $8.34-$8.59 range
  • Adjusted earnings per share are expected to be between $9.55 and $9.80 in the fiscal year, which is in line with the previous guidance
  • The management continues to expect cash provided by operations to be approximately $1.45 billion in FY25, and capital expenditure to be $500 million
  • For the first quarter of 2025, the company expects the worse-than-anticipated weather to create a headwind to revenue of around $25 million, and to EPS of about $0.10
ADVERTISEMENT